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a b s t r a c t
Conventional surgical techniques to seal and repair defects in highly stressed elastic tissues are insuf-
ﬁcient. Therefore, this study aimed to engineer an inexpensive, highly adhesive, biocompatible, and
biodegradable sealant based on a modiﬁed and naturally derived biopolymer, gelatin methacryloyl
(GelMA). We tuned the degree of gelatin modiﬁcation, prepolymer concentration, photoinitiator con-
centration, and crosslinking conditions to optimize the physical properties and adhesion of the photo-
crosslinked GelMA sealants. Following ASTM standard tests that target wound closure strength, shear
resistance, and burst pressure, GelMA sealant was shown to exhibit adhesive properties that were su-
perior to clinically used ﬁbrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in
small as well as translational large animal models proved GelMA to effectively seal large lung leakages
without the need for sutures or staples, presenting improved performance as compared to ﬁbrin glue,
poly(ethylene glycol) glue and sutures only. Furthermore, high biocompatibility of GelMA sealant was
observed, as evidenced by a low inﬂammatory host response and fast in vivo degradation while allowing
for adequate wound healing at the same time. Combining these results with the low costs, ease of
synthesis and application of the material, GelMA sealant is envisioned to be commercialized not only as a
sealant to stop air leakages, but also as a biocompatible and biodegradable hydrogel to support lung
tissue regeneration.
© 2017 Elsevier Ltd. All rights reserved.
1. Introduction
While traditional surgical closure and treatment of tissue de-
fects is achieved by sutures, staples, or wires, the application of
adhesives for different types of lesions is essential. The repair of
parenchymatous defects, such as in the lungs, liver, or kidney, is
particularly challenging since the consistency of these tissues does
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not facilitate strong fastening of sutures or staples. Within the
lungs, repetitive and quickly varying stress exerted by respiration
poses additional risks for failure of the repaired tissue, which is
further complicated by the non-sterile environment in the pul-
monary airways, creating the possibility of wound infection [1].
Even in tissues that can be sutured, the usage of adhesives may be
necessary to allow for better sealing, such as in the closure of small
stitching channels in a sutured artery wall [2]. Furthermore, limited
access to defect sites can make conventional suturing nearly
impossible since there is often not enough space to place sutures.
This issue may be solved by applying adhesive prepolymers that
polymerize on site, since these materials can be delivered to the
area of interest through thin applicators [3,4].
For maximum clinical efﬁcacy, tissue adhesives must demon-
strate strong adhesiveness to the tissue, not only to initially close
the defect, but to also allow for subsequent wound healing. During
this process, controlled degradation of the applied adhesive is
desirable [5]. The adhesive should also be biocompatible to avoid an
excessive host inﬂammatory response [6]. Furthermore, most
clinical applications require an adhesive with the ability to function
under wet conditions. Economic aspects to be considered include
application and curing within a reasonable period of time as well as
cheap and safe production of the material [7]. Besides these re-
quirements, further features may be desirable depending on the
target tissues. For example, defects in highly vascularized tissues
require adhesives with hemostatic properties, air or liquid leakages
necessitate effective sealants that withstand high pressures, and
lesions in ﬂexible tissues should be treatedwith elastic adhesives to
preserve their functionality. Thus, it is crucial to optimize the
adhesion and physical properties of tissue adhesives based on the
desired applications.
Various types of surgical adhesives and sealants that are
comprised of natural, synthetic, and semi-synthetic substances
have previously been developed [8,9]. The most common naturally
derived tissue adhesives are ﬁbrin- and collagen-based adhesives.
While these adhesives are biocompatible, their major drawbacks
are their low mechanical characteristics and adhesion strength as
well as high production costs and risk of infectious contamination,
resulting from the biological source of the materials [10,11]. On the
other hand, synthetic-based adhesives, especially clinically used
cyanoacrylates, exhibit improved adhesion strength as compared to
naturally derived sealants. However, they also provide low
biocompatibility and biodegradability, and evoke a foreign body
response or even necrosis due to toxic degradation products.
Moreover, due to their high stiffness, cyanoacrylate-based adhe-
sives impede physiological movement of elastic and soft tissues
such as in the lungs, heart, and blood vessels. Due to these limita-
tions, their usage is predominantly limited to external applications
such as the closure of skin wounds [10,11].
The adherence of most tissue adhesives is restricted to dry tissue
surfaces. Polymeric hydrogel-based sealants/adhesives can cross-
link even under wet conditions and can serve as ﬂuid barriers [12].
Predominantly, poly(ethylene glycol) (PEG)-based formulations
such as Coseal™, DuraSeal™ and FocalSeal® have been tested as
adhesives both in vitro and in vivo [13e18]. Unmodiﬁed PEG is non-
immunogenic, which favors its in vivo applications, whereas its
inert properties also avoid ingrowth of cells and do not allow tissue
healing and repair [16]. Furthermore, due to low mechanical and
adhesive characteristics of commercially available hydrogel-based
sealants, their clinical indications are predominantly focused on
the additional sealing of sutures, and not on the use in suture-free
surgical procedures [18,19].
Highly elastic hydrogel-based sealants have been developed
for the sealing and closure of elastic tissues such as the lungs.
However, most of these sealants lack the appropriate mechanical
properties, adhesion strength, and burst pressure performance
required for sealing of lung tissue leakages [4]. Adequate lung
leakage repair requires sealants with high elasticity that feature
strong mechanical and adhesive characteristics even under re-
petitive and extensive tension. After lung surgery, a prolonged air
leak is one of the most common complications, leading to
extended chest tube drainage time, which is associated with pain
and immobilization for the patient. This in turn increases the risk
of infections and broncho-pleural ﬁstulae and, subsequently, leads
to a longer hospital stay with associated higher healthcare costs
[20e23]. In order to prevent these complications, a variety of
natural and synthetic materials have been examined for use,
including ﬁbrin sealants, collagen-based sealants, and synthetic
glues [24]. For example, a photopolymerizable gelatin-based lung
sealant has been developed by covalently crosslinking di-tyrosine
in gelation in the presence of ruthenium and sodium persulphate
(SPS) [25]. The engineered sealants exhibited a lap adhesion
strength higher than commercially available adhesives, like ﬁbrin-
based products, and induced minor inﬂammation at the sealed
site in the lungs after 2 weeks. Although the optimized sealant
formulation was highly elastic with an extensibility of up to 650%,
its low elastic modulus (14 kPa) may not provide suitable cohesive
properties for lung sealing. In addition, the high concentrations of
SPS (20 mM) and porcine gelatin (17.5%) used to obtain this highly
elastic gelatin hydrogel induced toxicity in the in vitro studies.
Progel™ (Neomend, Irvine, CA, USA), based on human albumin
and a PEG crosslinker, has been commercialized as the ﬂagship
sealant product to stop air leakage in lung procedures and has
shown good burst pressure results [26,27]. However, the high cost
of isolating human albumin and the potential for disease trans-
mission causes concerns, as it does for other blood-derived
products. Another limitation of Progel™ is that, as a product
based on albumin and PEG, it lacks the function of hemostasis,
which may be required for sealing when there is blood emanating
from the wound. In summary, due to the above-mentioned limi-
tations of lung adhesives/sealants, the introduction of a new
biocompatible, highly adhesive, and elastic sealant with strong
mechanical properties is warranted.
Photopolymerization of gelatin methacryloyl (GelMA) is an
inexpensive and technically simple approach to fabricate hydrogels
for biomedical applications [28e33]. The cytocompatibility of
GelMA hydrogel has been previously proven in vitro and in vivo,
implying its potential to be used as a suitable biomaterial for
various tissue engineering applications [34e36]. While the engi-
neered formulation of GelMA hydrogel was suitable for 3D cell
spreading and engineering vascularized tissues, this particular
composition did not provide adequate adhesion to wet surfaces to
allow for usage as a ﬂexible and highly adhesive sealant.
The present study is aimed at engineering an optimized
formulation of GelMA hydrogels to act as tissue adhesives and
sealants for the closure of defects in highly stressed elastic tissues
such as the lungs. To obtain a GelMA sealant with high adhesion
strength, the degree of gelatin modiﬁcation, the prepolymer
concentration, the photoinitiator concentration, and the cross-
linking conditions of GelMA prepolymers were optimized.
Different ASTM (American Society for Testing and Materials)
standard tests were followed to characterize and optimize the
adhesive properties of the GelMA sealant, which were compared
to several clinically available ﬁbrin- and PEG-based glues/sealants.
Furthermore, the biocompatibility of the engineered GelMA
sealant was tested using a rat subcutaneous implantation model.
The in vivo performance of the engineered material for sealing
lung leakages was also evaluated using chronic rat and porcine
lung incision models.
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2. Materials and methods
2.1. Synthesis of gelatin methacryloyl (GelMA)
GelMA was synthesized as previously described [28,30]. Brieﬂy,
a 10% (w/v) porcine gelatin (Sigma-Aldrich, St. Louis, MO, USA) was
dissolved in phosphate buffered saline (PBS) and heated at 60 !C for
20 min. Drop-wise addition of 8% (v/v) methacrylic anhydride
(Sigma-Aldrich, St. Louis, MO, USA) under continuous stirring at
50 !C for 3 h was followed by dilutionwith PBS and dialysis against
deionized water at 40e50 !C for 7 days. After sterile ﬁltration and
lyophilization for 4 days, GelMA was stored at " 80 !C until
experimental use.
2.2. Preparation and characterization of GelMA hydrogels
Freeze-dried GelMA prepolymer was dissolved in PBS at con-
centrations of 10,15, 20 or 25% (w/v). After addition of 0.5% (w/v) 1-
[4-(2-Hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-
one (Irgacure 2959, BASF, Florham Park, NJ, USA) as photoinitiator
and dissolving at 80 !C, the prepolymer solutions were photo-
crosslinked through UV light irradiation (Omnicure S2000,
320e500 nm ﬁlter, EXFO Photonic Solutions Inc., Quebec, Canada)
to form hydrogels. For visualizing porosity, circular GelMA hydrogel
samples (5 mm in diameter) were fabricated, freeze-dried, sputter-
coated with gold and imaged by using a FEI/Philips XL30 FEG
scanning electronmicroscope (SEM) at 15 KV. Mechanical testing of
GelMA samples was conducted as previously published [37].
Brieﬂy, GelMA prepolymer solution was photocrosslinked to pro-
duce the following geometries: discs for compressive testing
(n ¼ 5; 6 mm in diameter and 1.5 mm in height) and cuboids for
tensile testing (n ¼ 5; 3 mm inwidth, 14 mm in length, and 1.5 mm
in thickness). The hydrogels were either directly analyzed or stored
in PBS at 37 !C for 24 h before being examined on an Instron me-
chanical tester (Instron 5542, Norwood, MA, USA). The strain rate
was set to 0.3 mm/min for compressive testing and 1 mm/min for
tensile testing. The compressive strength and the ultimate tensile
strength of the samples were determined at the point of failure
(rupture under tensile and compressive loading) of the hydrogels.
The compressive modulus was calculated based on the slope in the
linear portion of the stress/strain curves up to a 0.2 strain.
In order to analyze the swelling characteristics, GelMA hydrogel
samples (n ¼ 5) were allowed to swell in PBS at 37 !C for 1, 2 or 3
days. At the end of the experiment, excess liquid was gently
removed, and the wet weight was measured. After lyophilization,
the dry weight of the samples was measured, and the swelling ratio
was calculated as (wet weight-dry weight)/dry weight.
The crosslinking degree of GelMA in dependency on the cross-
linking time was assessed by proton nuclear magnetic resonance
(1H NMR) analysis. GelMA hydrogels were prepared at 25% (w/v)
polymer concentration and different ultraviolet (UV) exposure time
(0.5, 1, 2, 3 min). Uncrosslinked GelMA prepolymer was dissolved in
D2O at a concentration of 10 mg/ml. For crosslinked GelMA
hydrogels, deuterated dimethyl sulfoxide was used to partially
dissolve the hydrogels prior to 1H NMR analysis. In order to quan-
tify the degree of crosslinking, all spectra were normalized with
respect to the phenylalanine signal (d ¼ 6.9e7.3 ppm). According to
previous studies, the signals related to methacrylation appear at
three different peaks including two protons of methacrylate double
bonds located at d ¼ 5.30 and 5.7 ppm, and the methyl function of
the methacrylate group at d ¼ 1.91 ppm [38,39]. The degree of
crosslinking was calculated as below:
which represents the ratio of remaining C]C in the methacrylated
groups after the crosslinking process.
2.3. Wound closure test
The adhesion strengths of GelMA and the clinically available
surgical sealants Evicel® (Ethicon, Somerville, NJ, USA), Progel™
(NeoMend, Ervine, CA, USA) and Coseal™ (Baxter, Deerﬁeld, IL,
USA) were examined by using the standard test method for wound
closure strength of tissue adhesives and sealants, ASTM F2458-05,
with some modiﬁcation. In brief, fresh porcine skin from a local
slaughterhouse was prepared by removing the adipose tissue layer
and cutting the sample into rectangular sections (5 mm $ 15 mm).
While unused, porcine skin was kept moist in gauze soaked in PBS.
Before use, porcine skin was blotted dry to remove excess liquid,
and each end of the skin strip was ﬁxed onto two poly(methyl
methacrylate) slides (30 mm $ 60 mm) with Krazy glue (Wester-
ville, OH, USA), leaving a 6 mm section of skin between the slides.
The porcine skin strip was then cut apart using a razor blade
(Fig. S3), and petroleum jelly was applied with a syringe to the ends
of the desired adhesive application area in order to conﬁne the
prepolymer before crosslinking. Afterwards, 40 ml of the desired
adhesive to be tested was applied on the tissue, and in the case of
GelMA sealant, was irradiated with UV light.
The control glues were applied according to the manufacturers'
instructions: For Evicel® sealant, separate vials of thrombin and
ﬁbrinogen were thawed, placed into the applicator, and allowed to
mix and polymerize as they were sprayed onto tissue. For Coseal™
sealant, two components of PEG were allowed to mix within the
applicator as they were applied onto tissue and polymerized on
contact. For Progel™ sealant, human serum albumin and a PEG
crosslinker were kept in two separate components, andweremixed
when sprayed onto tissue and cured upon contact. After 1 h of in-
cubation in PBS, the two plastic slides were placed into an Instron
mechanical tester, with special attention paid to the placement of
the two sides of the samples in order to minimize the effect of any
additional stress due to misalignment. The adhesive strength of a
sealant samplewas determined at the point of tearing using a strain
rate of 1 mm/min. Each tested adhesive group contained four to
seven samples.
2.4. Lap shear test
The shear strength of GelMA sealant, Evicel®, Progel™ and
Coseal™ was examined according to the standard test method for
strength properties of tissue adhesives under lap-shear by tension
loading, ASTM F2255-05. Gelatin coating solution was prepared by
dissolving porcine gelatin 20% (w/v) in PBS at 80 !C. The top region
(10mm $ 15mm) of two glass slides (10mm $ 50mm in total) was
Degree of Crosslinking ðDCÞ% ¼
!
1 " Areaðmethacrylate groupsÞ
Areaðphenylalanine signalÞ
"
$ 100;
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coated with gelatin, which was allowed to dry at room temperature
[40]. Afterwards, 20 ml of the desired adhesive was applied on a
10 mm $ 10mm area on top of the gelatin coating of one glass slide
(Fig. S4), after which another gelatin-coated glass slide was placed
over the adhesive, and in the case of GelMA sealant, was followed
by irradiation with UV light. The two glass slides were placed into
an Instron mechanical tester for shear testing by tensile loading
with a strain rate of 1 mm/min. The shear strength of the sealant
sample was determined at the point of detaching. Each tested ad-
hesive group contained ﬁve samples.
2.5. In vitro burst pressure test
The burst pressure of GelMA sealant, Progel™, Evicel® and
Coseal™ was tested by using a standard test method for burst
strength of surgical sealants, ASTM F2392-04. Collagen sheets
(40 mm $ 40 mm) were soaked in PBS prior to sample preparation.
A circular defect (3 mm in diameter) was created in the center of a
collagen sheet that was placed between two Teﬂon sheets
(35 mm $ 35 mm) (Fig. S5). 50 ml of the desired adhesive solution
was injected on the defect and, in the case of GelMA, the prepol-
ymer was irradiated with UV light. Afterwards, the collagen sheet
was placed into the burst pressure testing system, consisting of a
pressure detection and recording unit and a syringe pump, that
applied air with continuously increasing pressure towards the
samples until bursting. Each tested adhesive group contained ﬁve
samples.
2.6. In vitro degradation test
The in vitro degradation was examined by means of a
collagenase-based assay. Disc-shaped GelMA samples (d ¼ 5 mm;
h ¼ 4 mm) with prepolymer concentrations of 10, 15, 20 and 25%
(w/v) were formed by using different UV crosslinking times ranging
from 0.5 to 3min. After dry weightmeasurement, the samples were
incubated with 2 mg/ml collagenase (in PBS) for 1, 3, 5, 7 or 10 days
(n ¼ 3 per condition and observation period). At the end of the
incubation period, the dry weight of the samples was measured
again, and their degradation was calculated based on the weight
loss.
2.7. Cytotoxicity of uncrosslinked GelMA prepolymer
In order to test the cytotoxicity of the GelMA prepolymer,
various concentrations of GelMA (10, 15, 20 and 25% (w/v)) were
prepared in Dulbecco’s Modiﬁed Eagle’s medium (DMEM) cell
culture media. The solutions were transferred into 24 well plates,
and 3000 3T3 cells per ml were added (100 ml). The cell viability was
assessed after 24 h using a calcein-AM/ethidium homodimer live/
dead assay.
2.8. Animal experiments
All small animal experiments were conducted in male Wistar
rats weighing 200e250 g, obtained from Charles River (Wilming-
ton, MA, USA), housed in a local animal care facility (PRB, Cam-
bridge, MA, USA) and fed ad libitum. Anesthesia and analgesia were
initiated and supported by isoﬂurane inhalation (2.0e2.5% (v/v))
and subcutaneous carprofen administration (5 mg/kg/d). The large
animal experiments were performed on 3 pigs weighing 40e50 kg,
obtained from Parsons farms (MA, USA), housed in a local animal
care facility (ARF at Beth Israel Deaconess Medical Center, Boston,
MA, USA) and fed ad libitum. Anesthesia and analgesia were initi-
ated and supported by isoﬂurane inhalation (5%/ 1e3% (v/v)) and
intramuscular tiletamine/zolazepam administration (6.6 mg/kg).
Postprocedural analgesia was maintained by fentanyl-TTS (2e4 mg/
kg) and intramuscular buprenorphine (0.03 mg/kg).
All experiments strictly followed the NIH “Guide for the Care
and Use of Laboratory Animals” and were approved by the local
animal care committees (HMA Standing Committee on Animals and
Institutional Animal Care and Use Committee at Beth Israel
Deaconess Medical Center; protocol numbers 05055 and 029-
2015).
2.9. Subcutaneous implantation of GelMA hydrogels in rats
Subcutaneous implantation of GelMA in rats (n ¼ 6) was con-
ducted as recently published [36,41]. After induction of general
anesthesia, small separated subcutaneous pockets were bluntly
prepared through short dorsal skin incisions (10mm in length), and
25% (w/v) GelMA samples (n ¼ 18) were implanted. After
anatomical wound closure, the animals were allowed to recover
from anesthesia. After 3, 7 or 28 days, the animals were euthanized
by CO2 inhalation, and the implants including adjacent tissue were
explanted and further processed for histology.
2.10. Evaluation of the performance of GelMA sealant in a rat lung
leakage model
In order to examine the suitability and effectiveness of GelMA as
sealant for lung leakages in vivo, a rat model was developed based
on previous literature [27]. After induction of inhalative anesthesia,
rats were orally intubated and subsequently ventilated (frequency
80 per min; tidal volume 3 ml) maintaining isoﬂurane anesthesia.
Through a right lateral thoracotomy in the sixth intercostal space, a
standardized lung lobe incision (3 mm in length; 5 mm in depth
towards the hilum) was generated with a No.11 surgical blade. All
animals showed outbreak of air bubbles and small amounts of
blood through the incisions. Immediately, under ventilation arrest,
50 ml GelMA prepolymer solution (n ¼ 7), Evicel® (n ¼ 3) or Pro-
gel™ (n ¼ 6) was administered and cured for 2 min for Progel™, or
0.5 min in case of GelMA under UV light (Fig. 4a and b). As addi-
tional control, leaking lungs (n ¼ 6) were sutured with a “Z” stitch
using 6-0 polypropylene sutures (Ethicon, Somerville, NJ, USA).
After having re-established ventilation, leakage from the sealed
injury was tested by application of warm saline solution, whereas
no leakagewas detected after single use of the sealants in any of the
animals. The thorax was anatomically closed, followed by de-airing
of the pleural space by means of a custom-made thorax drainage
system. In case of chronic experiments, animals were allowed to
recover from anesthesia under sustained ventilation.
Directly after defect sealing (n ¼ 18), at day 7 (n ¼ 6) and day 28
(n ¼ 3), the animals were euthanized. Histology and immunohis-
tology were performed from explants at day 7 (n ¼ 3) and day 28
(n ¼ 3), and burst pressure measurements were conducted at day
0 (n ¼ 18) and day 7 (n ¼ 3). For burst pressure testing, the trachea
was occlusively intubated and connected to a split tubing system
linking a pressure detection and recording unit and a syringe pump
with the lungs of the rat (Fig. 4c). Under continuous air injection,
the lungs were inﬂated, and the increasing pressure was recorded
up to the point of material burst or detachment or tissue burst. The
time point and type of sealant failurewas additionally visualized by
conducting the experiment in a water bath, resulting in air bubbles
rising from the leakage site. Burst pressure measurements in non-
injured lungs (n ¼ 3) served as additional controls.
2.11. Evaluation of the performance of GelMA sealant in a porcine
lung leakage model
Intending translational analysis, GelMA was tested in a
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previously published chronic porcine lung leakage model [25]. Af-
ter induction of general anesthesia, pigs were orally intubated and
subsequently ventilated (frequency 20 per min; tidal volume 10ml/
kg) maintaining isoﬂurane anesthesia. Through a right lateral
thoracotomy, a standardized visceral pleural defect (15 mm in
length; 15 mm in width; 1 mm in depth) was generated with a
scalpel (Fig. 5a). All animals showed outbreak of air bubbles
(d > 2 mm) and small amounts of blood through the incisions
during a submersion test with intrapleural warm saline solution
(Fig. 5b). Immediately, under ventilation arrest, 500 ml GelMA
(n ¼ 3) was administered and cured for 1 min under UV light
(Fig. 5c). After having re-established ventilation, leakage from the
sealed injury was tested again by application of warm saline solu-
tion, whereas no leakage was detected after single use of the
sealants in any of the animals. The thorax was anatomically closed,
followed by de-airing of the pleural space by means of a thorax
drainage system. Afterwards, animals were allowed to recover from
anesthesia under sustained ventilation. The surgical procedure is
presented in Video S1.
Supplementary video related to this article can be found at
http://dx.doi.org/10.1016/j.biomaterials.2017.06.004.
Pleural ultrasound imaging was performed on postoperative
days 7 and 14 to exclude a pneumothorax, using an Acuson Sequoia
C512 sonography system (Siemens Healthcare, Erlangen, Germany).
Fourteen days after surgery, following humane euthanasia of the
animals, the sealed defect area was excised and further processed
for histology.
2.12. Histology and immunohistology
Histology and immunohistology were conducted on
paraformaldehyde-ﬁxed 4e6 mm parafﬁn and cryo-sections of the
explants as previously reported [42]. Hematoxylin/eosin (H & E)
staining was performed to obtain microscopic overview. Masson
trichrome staining allowed for depicting of connective tissue. For
immunohistology, the primary antibodies anti-CD3, anti-CD68
(both from Abcam, Cambridge, MA, USA) and anti-Mac-2 (Cedar-
lane, Burlington, ON, Canada), and Alexa Fluor®-conjugated sec-
ondary antibodies (Life Technologies, Carlsbad, CA, USA) were used.
Immuno-labelled sections were covered with DAPI-containing
Vectashield mounting medium (Vector Labs, Peterborough,
United Kingdom) and visualized on a LSM 880 confocal microscope
(Zeiss, Jena, Germany).
2.13. Statistics
Continuous variables displayed as mean values ± standard de-
viations. Group comparisons were conducted by one-way-ANOVA
with Bonferroni post-hoc tests. P-values <0.05 were assumed to
indicate signiﬁcance. Data analysis was conducted with GraphPad
Prism (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. Physical characteristics of GelMA sealant
Prior to the examination of the suitability of GelMA hydrogels to
act as sealants, the physical properties of engineered hydrogels in
dependency on different GelMA concentrations (10, 15, 20 and 25%
(w/v)) were tested. Freshly photocrosslinked hydrogels and
hydrogels soaked in PBS for 24 h underwent compressive me-
chanical testing. Under both conditions, higher GelMA concentra-
tions resulted in increased values for the compressive modulus
(from 36 ± 16 kPa for 10% GelMA to 156 ± 48 kPa for 25% GelMA)
and compressive strength (Figs. S1a and b). The highest
compressive strength (1018± 167 kPa)was obtained for a 25% (w/v)
GelMA hydrogel (Fig. S1b). After 24 h of incubation in PBS, a 10e15%
drop in compressive strength was observed for all GelMA formu-
lations, as shown in Fig. S1b. Tensile testing also revealed the
highest elastic modulus (180 ± 34 kPa) and increased ultimate
tensile strength (53 ± 17 kPa) for a 25% (w/v) GelMA when
compared to other GelMA formulations (Figs. S1c and d). In addi-
tion, the elasticity of GelMA hydrogels varied between 30% and 40%
as the GelMA concentrationwas changed from 10% (w/v) to 25% (w/
v) in uniaxial tensile tests (Fig. S1c).
The swelling ratios of GelMA hydrogels at different concentra-
tions were calculated by dividing the measured weights of the
hydrogel samples after 1e3 days of incubation at 37 !C in PBS by
their corresponding dry weights. As shown in Fig. S1e, the swelling
ratios of the hydrogels decreased with increasing GelMA concen-
trations. However, the swelling ratio values changed only slightly
over time, indicating that equilibrium states were achieved after
24 h. SEM images of the GelMA hydrogels revealed the resulting
hydrogels having highly porous structures (Fig. S1f).
Based on 1H NMR analysis, the degree of crosslinking was
calculated from the disappearance of the C]C bonds correlated to
the methacrylated groups at d ¼ 5.30 and 5.7 ppm. The degree of
crosslinking was above 78% after 0.5 min UV exposure time.
Furthermore, after 1 min reaction time, 84% of the originally
methacrylated groups were consumed (Fig. S2). Interestingly, the
degrees of crosslinking were 92% and >95% after 2 min and 3 min,
respectively, indicating that the reaction rate decreased over time.
Overall, the hydrogel crosslinking was approximately completed
(>95%) after 3 min UV exposure time. Therefore, we used 3 min as
the optimal reaction time to form fully crosslinked hydrogels for
the following experiments.
3.2. In vitro adhesion strength, shear strength and burst resistance
of GelMA sealant
Properties that are important for effective sealants, including
adhesion strength, shear strength, and burst pressure, were
examined in vitro according to ASTM standard tests. In these tests,
the sealing capability and adhesion strength of GelMA sealants,
produced by using different GelMA concentrations and photo-
crosslinking times, were compared to the clinically established
sealants such as Evicel®, Coseal™ and Progel™.
The adhesion strength of the engineered sealants was measured
by using a modiﬁed wound closure test based on ASTM F2458-05
(Fig. S3). Higher concentrations of GelMA led to higher adhesive
strengths. Speciﬁcally, the 25% GelMA hydrogels, that was cross-
linked by using 3 min light exposure time, attained an adhesive
strength of 49 ± 9 kPa, which was higher than those of Evicel®
(19 ± 17 kPa) and Coseal™ (26 ± 5 kPa) and lower than that of
Progel™ (78.7 ± 14 kPa) (Fig. 1a). In addition, it was found that the
adhesive strength was also slightly affected by the light exposure
time (Fig. 1b): a 23% enhancement in adhesion strength (from
40 ± 5 kPa to 49 ± 9 kPa) was observed when the exposure time
increased from 0.5 to 3 min for a 25% GelMA hydrogel, but this was
not statistically signiﬁcant.
The shear strength of the engineered sealants was also charac-
terized by using a modiﬁed lap shear test based on ASTM F2255-05
(Fig. S4). Similar to the wound closure test, the highest shear
strength was obtained for the 25% (w/v) GelMA (262 ± 55 kPa)
photopolymerized by using 3 min light exposure time, which was
signiﬁcantly higher than for Evicel® (207 ± 67 kPa), Coseal™
(70 ± 21 kPa) and Progel™ (226 ± 33 kPa) (Fig. 1c). In addition,
increasing the UV exposure time from 0.5 to 3 min enhanced the
shear strength of a 25% GelMA sealant from 175 ± 23 kPa to
262 ± 55 kPa as shown in Fig. 1d.
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In order to test the burst pressure of the engineered sealant,
continuously increasing air pressure was exerted on sealants
covering a standardized defect in a collagen sheet based on ASTM
F2392-04 (Fig. S5). The burst pressure of GelMA sealant signiﬁ-
cantly enhanced from 3.0 ± 0.6 kPa to 14.9 ± 5.7 kPa as the GelMA
concentration was increased from 10% (w/v) GelMA to 25% (w/v)
GelMA at 3 min light exposure time (Fig. 2a). In addition, a 25% (w/
v) GelMA sealant outperformed all three commercially available
adhesives, reaching a burst pressure of 14.9 ± 5.7 kPa compared to
1.5 ± 0.7 kPa for Evicel®, 1.6 ± 0.2 kPa for Coseal™, and 4.4 ± 0.4 kPa
for Progel™ (Fig. 2a). It should be noted that even at the lowest
tested concentration (10%), the burst pressure of GelMA was two-
fold higher than those of Evicel® and Coseal™. Moreover, the
burst pressure value for a 25% GelMA sealant was enhanced
approximately 5-fold by increasing the UV exposure time from 0.5
to 3 min (Fig. 2b).
Taken together, the mechanical testing and ASTM standard tests
for adhesives showed excellent mechanical and adhesive proper-
ties for GelMA sealants produced by using 25% GelMA prepolymer
concentration. The wound closure strength, the shear resistance
and especially the burst pressurewere signiﬁcantly higher for a 25%
(w/v) GelMA sealant as compared to clinically available PEG-based
and ﬁbrin-based control glues. Therefore, this formulation was
used for the in vivo examination of its biocompatibility using a rat
subcutaneous implantation model and its biofunctionality using a
lung incision model in both small and large animals.
Fig. 2. In vitro burst pressure of GelMA sealant. Burst pressure values for commercially available sealants and GelMA sealants produced by (a,b) varying GelMA concentrations at
3 min UV exposure time and (c,d) changing UV exposure time for a 25% GelMA sealant. (**p < 0.01; ***p < 0.001; ****p < 0.0001).
Fig. 1. In vitro sealing properties of GelMA sealant. (a,b) Standard wound closure test using porcine skin as a biological substrate to test the in vitro adhesion strength of GelMA
and different commercially available sealants. (c,d) Standard lap shear test to determine the shear strength of GelMA sealant in comparison to different commercially available
sealants. The effect of GelMA prepolymer concentrations on the adhesion strength of hydrogels formed at 3 min UV exposure time is shown in a,c; the effect of the UV exposure
time on the adhesion strength of a 25% GelMA sealant is shown in b,d. (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001).
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3.3. In vitro degradation of GelMA sealant
The degradation of the GelMA hydrogels was examined using a
collagenase-based in vitro assay. Low prepolymer concentrations
(p < 0.0001) and short UV crosslinking times (p < 0.0001) resulted
in signiﬁcantly accelerated degradation as compared to higher
concentrations and longer crosslinking times (Fig. S6) (Table S1).
3.4. Cytotoxicity of uncrosslinked GelMA prepolymer
The cytotoxicity of uncrosslinked GelMA prepolymer was exam-
ined by using 3T3 cells and a live/dead assay for different prepolymer
concentrations. As shown in Fig. S7, after one day of incubating 3T3
cells with different concentrations of GelMA prepolymer solutions,
high cell viability was observed for all tested conditions, conﬁrming
that uncrosslinked GelMA prepolymer did not induce cytotoxicity.
3.5. Biocompatibility of GelMA sealant in rats
The in vivo biocompatibility of GelMA sealant was examined 3, 7
and 28 days after subcutaneous implantation of the hydrogels in
rats. Histological staining revealed no relevant monocyte inﬁltra-
tion around or into the sealant (Fig. 3a,d,g). At days 3 and 7, mac-
rophages were observed around the implants (Fig. 3b,e); however,
at day 28, they were no longer present (Fig. 3h). At all time points,
no lymphocyte inﬁltration was detected (Fig. 3c,f,i).
3.6. GelMA sealant for lung leakages in a rat model
A rat model of standardized lung leakage was established to test
the suitability and effectiveness of GelMA sealant for in vivo sealing
of pulmonary lesions in the absence of any additional conventional
surgical methods, for example, suturing or stapling (Fig. 4a and b).
The initial sealing strength of GelMA aswell as the burst pressure of
the sealed lung tissue during autologous defect repair at the post-
operative day 7were examined. All rats survived the surgeryand the
desired follow-up period up to day 28. No clinical signs of post-
operative pneumothorax were observed, and at the end of the
follow-upperiod, no lung leakagewas found. In order toquantify the
sealing strength, burst pressure measurements were conducted on
the GelMA-sealed lungs on day 0 and day 7, and on healthy lungs as
controls (Fig. 4cee). Evicel®, Progel™ and polypropylene sutures
only were used as controls in this experiment. In the case of GelMA,
the typical mode of failure was not bursting of the material, but
rather detachment from the lung surface at a burst pressure value of
5.7 ± 1.5 kPa, or bursting of native lung tissue outside of the defect
area (Fig. S8a). On the contrary, Evicel® and Progel™ failed by direct
material bursting at 2.7 ± 0.7 kPa and 2.2 ± 0.7 kPa, respectively,
which was due to the low mechanical properties of the adhesives
(Fig. S8b). In case of sutures, the lung tissue burst around the stitch
channels at 3.1 ± 0.7 kPa. The burst pressure of GelMA sealant
immediately after curing on the lung tissue was signiﬁcantly higher
in comparison to Evicel® (p< 0.01), Progel™ (p< 0.001) and sutures
Fig. 3. In vivo biocompatibility of GelMA sealant. Immunohistology analyses (aec) 3, (def) 7, and (gei) 28 days after subcutaneous implantation in rats showed initial implant-
surrounding macrophage (CD68) invasion (arrows in b,e), which was no longer present at day 28 (h). At no point were there signs of lymphocyte (CD3) inﬁltration (c,f,i). (a,d,g, H &
E staining; asterisks, GelMA sealant; scale bars, 200 mm).
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only (p < 0.01) (Fig. 4d). Due to the extensive air leakages from the
Evicel®- and Progel™-sealed lung tissue, leading to lethal pneu-
mothorax shortly after extubation, the chronic survival tests were
continued by using 25% GelMA sealant only. Seven days after sur-
gery, the burst pressure of GelMA-sealed lung tissue was even
further elevated as compared to day 0 and reached values that were
equal to the burst pressure of native healthy rat lung tissue
(7.0 ± 2.2 kPa versus 6.9 ± 1.5 kPa) (Fig. 4e). In some burst pressure
experiments on GelMA-sealed lungs, it was not the sealant that had
failed, but instead the native lung tissues had burst in other areas.
Therefore, the reported burst pressure value is the actual rat lung
burst pressure. This observation highlights the need for using a large
animal model for accurate testing of the performance and sealing
capability of the engineered sealants.
Histology assessment of the sealing area revealed stable
collagenous defect repair tissue under the GelMA cover at day 7
after sealing, while at day 28, cellular invasion into the hydrogels
and consecutive matrix remodeling were observed (Fig. 4fek).
Immunohistology demonstrated that only a minor number of the
invading cells had an inﬂammatory phenotype (Fig. 4m and n).
3.7. GelMA sealant for lung leakages in a translational pig model
A translational porcine lung lesion model was used to further
Fig. 4. In vivo sealing capacity of GelMA sealant using a rat lung incision model. (a,b) GelMA sealant is applied on a lung leakage via a small lateral thoracotomy and UV-
crosslinked until the incision was sealed. (c) Schematic of the setup used to measure the lung burst pressure after sealing: A syringe pump and a pressure sensor are con-
nected to the trachea allowing for pressure monitoring during lung inﬂation in a closed system. (d) Burst pressure of GelMA-sealed, Evicel®-sealed, Progel™-sealed and sutured
lungs immediately after material application demonstrating that the burst pressures of GelMA sealant-treated lungs were signiﬁcantly higher than those in all other groups. (e)
Burst pressure of GelMA-sealed lungs on day 0 and day 7 post surgery compared to healthy lung: 7 days after surgery, the burst pressure of GelMA-sealed lungs was further
increased as compared to day 0 and reached the level of healthy lung tissue. (f,g) H & E and (h,k) masson trichrome stainings of GelMA-sealed lung tissue sections at days 7 and 28.
Histologically, defect repair tissue was observed under the GelMA cover 7 days after lung leakage sealing (asterisks in f), including stable collagenous tissue layers (asterisks in h).
After 28 days in vivo, host cells had invaded the GelMA seal and matrix remodeling had occurred (hashs in g,k). Immunohistology of GelMA-sealed lung tissue sections at (m) day 7
and (n) day 28 revealed only sparse presence of CD3- and CD68-positive cells around the GelMA implants (asterisks in m, defect repair tissue; hashs in n, remodeled hydrogel
cover). (scale bars, 100 mm and 50 mm in the high magniﬁcation pictures, respectively; **p < 0.01; ***p < 0.001).
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demonstrate the suitability of a 25% GelMA hydrogel as a lung
sealant without the use of any additional conventional surgical
methods such as suturing or stapling (Fig. 5aec, Video S1). Three
pigs were tested and all animals survived the surgery and the
desired follow-up period of 14 days. No clinical or sonographic
signs of pneumothorax were observed during the follow-up
(Fig. 5dee). After 14 days, the defect sites were covered by con-
nective repair tissue, while GelMA sealant had disappeared.
Fig. 5. In vivo sealing capacity of GelMA sealant using a porcine lung incision model. (a-c) A right lung lobe is exposed via a small lateral thoracotomy, a standardized defect is
created (broken lines in a and b) and sealed by photocrosslinking of GelMA sealant (broken line in c). (d,e) Ultrasound studies on the sealed lung tissue at postoperative days 7 and
14: Freedom from pneumothorax was conﬁrmed by sonography, as shown in a representative ultrasound image at day 14. (f-h) Representative histological sections of the GelMA-
sealed site after 14 days revealed sufﬁcient wound healing (asterisks in f) including a stable collagenous (blue) defect cover (asterisks in g), in comparison with non-injured
parenchymatous lung tissue (h). For high magniﬁcation pictures, see Fig. S9. (i) By immunohistological staining of the GelMA-sealed tissue, no lymphocyte inﬁltration (CD3)
was observed, and only mild macrophage accumulation (Mac-2) occurred. (f, H & E staining; g,h, masson trichrome staining; scale bars in f,g,h, 200 mm; scale bar in i, 100 mm). (For
interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
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Histological evaluation of the injured area revealed strong collag-
enous defect repair tissue (Fig. 5feg) (Fig. S9), whereas the sur-
rounding area exhibited healthy lung parenchyma (Fig. 5h).
Immunohistology revealed no signs of lymphocyte inﬁltration and
only mild macrophage accumulation in the sealed defect area
(Fig. 5i).
4. Discussion
The use of a gelatin-based adhesive to seal lung defects has been
recently suggested [25]. Photopolymerization of tyrosine-enriched
gelatin in the presence of ruthenium and SPS has resulted in
hydrogels with promising tensile and adhesive characteristics.
However, the in vivo toxicity of ruthenium and SPS caused a mild
inﬂammatory response after sealing of sheep lung defects.
Furthermore, the developed ruthenium and SPS sealant was used
only with additional sutures and no control group without the
adhesive was tested. Although adequate sealing of sheep lung tis-
sues was claimedwhen using the engineered gelatin-based sealant,
the reported results were described only qualitatively. In summary,
this previous gelatin-based adhesive sealed lung leakages only in
the presence of additional sutures, and caused mild local inﬂam-
mation. In contrast, the GelMA sealant in our study was examined
in a rat lung leakage model without additional use of sutures or
staples. A single application of GelMA sealant with only 50 ml of
prepolymer outperformed ﬁbrin glue, Progel™, and polypropylene
sutures with a two-fold increase in burst pressure directly after
curing of the sealants. The burst pressure values of GelMA-sealed
lung tissues reached a level that was similar to that of native rat
lung tissue, and at day 7 after surgery, the burst pressure of GelMA-
sealed lungs was further elevated. Therefore, most of the lungs did
not burst at the defect site (in contrast to ﬁbrin glue), but in initially
unimpaired tissue regions. Since by day 7, new tissue had grown on
the sealed defect site, the supra-physiological burst pressure values
at day 7 may not be attributed to the GelMA sealant alone. How-
ever, directly after sealing at day 0, the burst pressure levels of
GelMA-sealed lungs were already close to those of healthy lungs,
and the initial sealing strength was high enough to bridge the time
period until defect repair by ingrowing autologous tissue.
In situ photopolymerization of the GelMA prepolymers facili-
tates easy delivery even to technically demanding locations, such as
during minimally invasive surgery, and allows for curing of the
sealant exactly according to the required geometry of the tissue to
be sealed, which is an advantage over pre-fabricatedmaterials such
as hemostyptic collagen or ﬁbrinogen/thrombin scaffolds [43,44].
Besides physical interconnection of the curing sealant with the
tissue surface, gelatin offers additional interaction with tissues in
defect areas. Since gelatin contains multiple domains that bind to
cell-surface receptors and extracellular matrix proteins, initial
connection of the sealant to the tissue as well as subsequent cell
attachment to and cell growth on the sealant is promoted [45].
Gelatin has these properties in common with collagen, which it is
derived from. However, xenogeneic collagen exhibits increased
antigenic response as compared to xenogeneic gelatin due to its
helical structure and the higher content of tyrosine, tryptophan,
and phenylalanine, resulting in enhanced formation of aromatic
radicals [46,47].
It has been reported that native lung tissue has an elasticity of
around 40% [48,49]. As we plan to use the engineered hydrogel as a
lung sealant, the 25% GelMA formulation with elasticity similar to
lung tissue may be suitable for future experiments. Due to the high
ultimate strength of the 25% (w/v) GelMA hydrogel, it is expected
that the engineered formulation could structurally withstand the
forces exerted on human lung tissue and adjacent adhesives since,
even in patients under invasive ventilation, the positive pressure in
the lungs rarely reaches more than 5 kPa [50]. These values are
already substantially higher than the maximum pressures exerted
on the lung tissue during physiological breathing, reaching values
within 0.13e0.26 kPa of atmospheric pressure [51]. The optimized
mechanical properties of the engineered GelMA sealant can offer
certain ﬂexibility and stiffness, which will not limit the lung tissue
movement and allow normal function while minimizing tissue
damage.
The signiﬁcantly reduced swelling ratio in 25% GelMA sealant, as
compared to other formulations, indicates improved stability of the
hydrogels against swelling and may thereby avoid the risk of
additional stress on the surrounding tissue by material expansion
after application.
Human ﬁbrin-based glues are probably the most widely used
surgical adhesives, since they provide adequate hemostasis in
many surgical scenarios and have low immunogenicity. Unfortu-
nately, their mechanical properties are low and their production is
expensive. Conversely, GelMA sealant has proven to have beneﬁcial
mechanical and adhesive properties and also a low manufacturing
cost. Furthermore, the human origin of ﬁbrin potentially allows for
viral diseases transmission, such as hepatitis C or human immu-
nodeﬁciency virus, although no transmission has yet been proven
[11]. GelMA sealant is produced from porcine or bovine gelatin that
can be harvested under sterile conditions from animals in
pathogen-free barrier facilities, so that the risk of transmission or
infection may be even lower than that of human ﬁbrin-based
products.
Several PEG-derived sealants have been tested experimentally
as well as clinically [13e18]. FocalSeal® is a light-activated sealant
that has been reported to support the closure of pulmonary air
leaks after previous suturing or stapling in large animals and
humans [17,18]. However, its usage without sutures or staples is not
recommended. The application of FocalSeal® was approved by the
Food and Drug Administration (FDA) in 2000, but due to high
manufacturing costs and the need of a three step procedure for its
application (the use of a primer prior to the sealant application,
followed by light exposure), impeding the adoption of the sealant,
the product was withdrawn from the market in 2003, even though
it could be successfully used to seal lung tissue defects. Progel™, a
hydrogel-based lung sealant composed of human serum albumin
and a PEG derivative, has been approved by the FDA for the intra-
operative application during pulmonary resection. In a rat model, it
has been reported that Progel™ increases the initial lung burst
pressure after sealing of a defect, when compared to ﬁbrin glue
(10.3 ± 2.5 versus 4.1 ± 2.0 kPa) [27]. In our rat study, Progel™ did
not perform signiﬁcantly better in comparison to the ﬁbrin glue
Evicel®. Furthermore, it was not possible to even reach the true
burst pressure level of GelMA sealant, as the native rat lung tissue
burst at non-defect sites before reaching this value. A multicenter
trial in pulmonary resection patients showed that Progel™ appli-
cation with suturing/stapling was superior to suturing/stapling
only [52]. The length of hospital stay was reduced by one day, and
after 30 days, 35% of the Progel™-treated lungs were leak-free
(versus 14% in the control group). Although this difference was
statistically signiﬁcant, the 65% remaining or re-occurring leaks
leave much room to improve the air leakage sealing technique with
Progel™. In our study, we have shown that the burst pressure and
lap shear strength of GelMA sealant were higher than those of
Progel™. In addition, GelMA sealant proved to be an effective lung
sealant in small and large animal models even in the absence of
additional suturing/stapling. Moreover, GelMA sealant showed rat
lung burst pressure values that were superior to those for poly-
propylene sutures only. Another disadvantage of Progel™ may be
caused by themanufacturing costs for extraction and puriﬁcation of
human serum albumin or production of the recombinant protein,
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respectively, whereas the use of Progel Platinum™ with recombi-
nant albumin is not yet approved in the U.S. In summary, due to the
above-mentioned limitations of Progel™ and the other clinically
available products, it is expected that the engineered GelMA sealant
in our study could be used as a biocompatible, easily applicable, and
affordable surgical sealant for the sealing of soft and elastic tissues
without the need for additional suturing/stapling.
The in vitro adhesive and cohesive properties of GelMA sealant
have been examined primarily by using standard wound closure,
lap shear and burst pressure. As reported in previous studies on
surgical sealants, these tests were performed with standard tissues
or tissue substitutes, respectively, in order to get reliable data on
the general sealing potential of the gelatin-based adhesives
[53e55]. Aiming to determine the sealing potential of GelMA
hydrogels on the target tissue lung, additional in vivo experiments
were conducted in two different animal models with lung lesions.
In order to translate GelMA application towards human use, the
present study particularly evaluated the in vivo performance of the
engineered hydrogel sealant in a porcine lung leakage model. The
experiments proved that GelMA is suitable for the sealing of sig-
niﬁcant pulmonary defects in large animals in the absence of
additional suturing/stapling and facilitated fast wound healing.
The ﬁndings on the high biocompatibility of GelMA sealant in
chronic small as well as large animal models conﬁrmed multiple
reports on the beneﬁcial biocompatibility of gelatin, which was
obviously not impaired by methacrylation and UV light-mediated
crosslinking [56]. GelMA hydrogels did not exert cytotoxicity, as
has been shown previously [28,35]. Additionally, our data demon-
strated that uncrosslinked GelMA prepolymers at different con-
centrations did not induce detectable cytotoxicity. In the present
study, subcutaneous implantation experiments revealed moderate
macrophage accumulation around the GelMA implants on days 3
and 7 that disappeared by day 28. Concordantly, there was mild
macrophage inﬁltration on days 7 and 28 after lung leakage sealing
in rats and on day 14 after implantation in pigs. These results are in
line with previous reports on a macrophage-based foreign body
response against gelatin-based hydrogel implants [57]. However,
the decrease inmacrophage accumulationwithin only 28 days after
implantation may indicate a mild foreign body reaction against the
implanted GelMA sealant. Further preclinical long-term studies
could add information on the time course of macrophage response
to GelMA implants as well as to the subtypes of macrophages
involved in this process. Such a subtype classiﬁcation may enable a
differentiation between macrophage accumulation in terms of
wound healing versus mild inﬂammatory response against the
implants.
After 14 days in the pig defect model, the repaired defect site
was still detectable, whereas GelMA was no longer present.
Twenty-eight days after the sealing of a rat lung leakage, histology
revealed substantial remodeling of the GelMA cover by invading
host cells. These results proved sufﬁcient wound repair within a
short period of time. Besides adequate wound healing, biodegra-
dation of the sealant seems to have happened, which might be
achieved by host collagenases, i.e. primarily the matrix metal-
loproteinases 1, 8 and 13 [58]. Moreover, the matrix metal-
loproteinase 9, also known as gelatinase B, may play an important
role for the biodegradation of the GelMA sealant, since it exerts a
strong cleavage activity on gelatin [59]. Rapid in vivo degradation of
gelatin-based biomaterials has been reported in previous studies
[33,60,61], supporting the validity of our present observation that
GelMA sealant underwent early degradation on rat and porcine
lung lesions. Our in vitro degradation tests also revealed that the
degradation kinetics of GelMA sealant were highly tunable, and
that GelMA hydrogels with the optimized prepolymer concentra-
tions degrade rapidly in vitro. Furthermore, it has been observed
that the degradation of the GelMA hydrogels is dependent on the
prepolymer concentration as well as the UV crosslinking time. This
may explain why GelMA had disappeared from the lung defect site
within 14 days after sealing, since the crosslinking time was only
0.5 min. However, 28 days after subcutaneous implantation of
thicker GelMA samples, no macroscopically relevant degradation
was observed. It may be hypothesized that the mechanical stresses
on the lung and collagenase/gelatinase activity in the serous pleural
ﬂuid had contributed to faster degradation of GelMA in this posi-
tion, or that the material remnants had simply detached after
defect repair.
In terms of hemostasis, GelMA sealant was sufﬁcient in stopping
mild hemorrhage from the generated rat and porcine lung lesions.
However, thorough investigation of the actual hemostatic potential
of the sealant should be performed in adequate bleeding models,
such as in a liver laceration model, which has been recently used to
test the effect of shear-thinning nanocomposite hydrogels when
applied in otherwise lethal hemorrhaging [36,41]. In this context,
appropriate modiﬁcation of GelMA sealant may allow for the cre-
ation of an effective sealant with strong hemostatic properties. Due
to the fact that the pulmonary airways are a non-sterile environ-
ment, frequently evoking severe infections after lung surgery,
antibacterial functionality may be another desirable property of a
pulmonary sealant [62]. This feature may be provided by including
silver or copper oxide nanoparticles or nanoparticle-carried anti-
biotic drugs within the sealant [63e65].
In the present study, we showed the successful application of
our engineered sealant on lung lesion sites that are easily acces-
sible. In real life scenarios, pulmonary defects may also occur in
areas with restricted accessibility. In these cases, it should be
possible to deliver the light for the crosslinking procedure by uti-
lizing small light probes that can be also used in minimally invasive
surgery to crosslink the applied biomaterials. Our future studies
will focus on designing such light sources to extend the spectrum of
applications of our engineered adhesive to minimally invasive
surgery, and to also allow for the sealing of defects with difﬁcult
access. Moreover, we will examine different non-UV-bound pho-
toinitiator systems for hydrogel crosslinking.
In our animal models, a small amount of GelMA prepolymer was
applied on the defect sites. When using a larger amount of the
material in real life scenarios, the high swelling potential of the
material should be considered. In order to avoid local compression
in restricted areas, only thin layers of GelMA hydrogel should be
created, the sealing efﬁciency of which was shown in the present
study.
5. Conclusions
Surgical glues are emerging biomedical tools that supplement
conventional techniques like suturing or stapling, and have the
strong potential to replace them. Besides general requirements,
such as high biocompatibility, the broad variety of possible defect
scenarios in different tissues demands adhesives with targeted
properties.
The present study reports the suitability, effectiveness, and
biocompatibility of a light-activated, gelatin-based hydrogel as a
sealant for highly stressed elastic tissues. ASTM standard tests as
well as chronic small and translational large animal models of lung
leakage in the absence of prior sutures or staples proved GelMA
sealant to exhibit excellent mechanical properties, including
wound closure strength, shear resistance, and burst pressure, all of
which outperformed clinical standard glues as well as sutures.
Furthermore, GelMA sealant was shown to avoid a relevant in-
ﬂammatory host response in vivo and to degrade quickly while
allowing for adequate wound healing at the same time. Combining
A. Assmann et al. / Biomaterials 140 (2017) 115e127 125
our results with the low costs, ease of synthesis and application,
and ﬂexibility that minimizes adjacent tissue damage by avoiding
mechanical compliance mismatch, GelMA sealant offers strong
potential for commercialization as a sealant for air leakages.
The data of the present study suggests that large-scale testing of
GelMA sealant in our translational large animal model should be
the viable next step in establishing a new lung sealant.
Author contributions
AA, NA and AK designed the experiments. AV, MGR, SB, ESS and
IN conducted the in vitro experiments. AA, AV, ESS, GUR and MGR
conducted the small animal experiments. GC and SG conducted the
large animal experiments. AA, AV, MGR, SB, IN, ESS, AK and NA
analyzed the in vitro experiments. AA, AV, MGR, AT, AK and NA
analyzed the small animal experiments. AA, GC, AK and NA
analyzed the large animal experiments. AA wrote the manuscript.
AK and NA provided major revisions. NA, AT and AK provided
comments to the manuscript. All authors reviewed the manuscript.
Acknowledgements
The authors gratefully acknowledge Lay-Hong Ang for her work
and support regarding histological and immunohistological
readout, and Mina Keshvardoost for her work in the degradation
experiments. AA acknowledges postdoctoral funding from the
German Heart Foundation, Frankfurt, Germany. SB acknowledges
funding from MIT-Italy program (Progetto Rocca) and Polimi In-
ternational Fellowship (PIF). The authors acknowledge funding
from the National Institutes of Health (AR057837, DE021468,
D005865, AR068258, AR066193, EB022403, EB021148), and the
Ofﬁce of Naval Research Presidential Early Career Award for Sci-
entists and Engineers (PECASE). N.A. acknowledges the support
from the American Heart Association (AHA, 16SDG31280010), FY17
TIER 1 Interdisciplinary Research Seed Grants from Northeastern
University, and the startup fund provided by the Department of
Chemical Engineering, College of Engineering at Northeastern
University.
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
dx.doi.org/10.1016/j.biomaterials.2017.06.004.
References
[1] H. Itano, The optimal technique for combined application of ﬁbrin sealant and
bioabsorbable felt against alveolar air leakage, Eur. J. Cardiothorac. Surg. 33
(2008) 457e460.
[2] M. Glickman, A. Gheissari, S. Money, J. Martin, J.L. Ballard, C.M.V. Surger,
A polymeric sealant inhibits anastomotic suture hole bleeding more rapidly
than gelfoam/thrombin - results of a randomized controlled trial, Arch. Surg-
Chicago 137 (2002) 326e331.
[3] N. Annabi, A. Tamayol, S.R. Shin, A.M. Ghaemmaghami, N.A. Peppas,
A. Khademhosseini, Surgical materials: current challenges and nano-enabled
solutions, Nano Today 9 (2014) 574e589.
[4] N. Annabi, K. Yue, A. Tamayol, A. Khademhosseini, Elastic sealants for surgical
applications, Eur. J. Pharm. Biopharm. Off. J. ArbeitsgemeinschaftPharmazeu-
tische Verfahrenstechnik eV 95 (2015) 27e39.
[5] S. Wolbank, V. Pichler, J.C. Ferguson, A. Meinl, M. van Griensven, A. Goppelt, et
al., Non-invasive in vivo tracking of ﬁbrin degradation by ﬂuorescence im-
aging, J. Tissue Eng. Regen. Med. 9 (2015) 973e976.
[6] L. Montanaro, C.R. Arciola, E. Cenni, G. Ciapetti, F. Savioli, F. Filippini, et al.,
Cytotoxicity, blood compatibility and antimicrobial activity of two cyanoac-
rylate glues for surgical use, Biomaterials 22 (2000) 59e66.
[7] W.D. Spotnitz, S. Burks, Hemostats, sealants, and adhesives III: a new update
as well as cost and regulatory considerations for components of the surgical
toolbox, Transfusion 52 (2012) 2243e2255.
[8] F. Scognamiglio, A. Travan, I. Rustighi, P. Tarchi, S. Palmisano, E. Marsich, et al.,
Adhesive and sealant interfaces for general surgery applications, J. Biomed.
Mater. Res. Part B Appl. Biomater. 104 (2016) 626e639.
[9] W.D. Spotnitz, S. Burks, Hemostats, sealants, and adhesives: components of
the surgical toolbox, Transfusion 48 (2008) 1502e1516.
[10] R. Bitton, E. Josef, I. Shimshelashvili, K. Shapira, D. Seliktar, H. Bianco-Peled,
Phloroglucinol-based biomimetic adhesives for medical applications, Acta
Biomater. 5 (2009) 1582e1587.
[11] M. Mehdizadeh, H. Weng, D. Gyawali, L. Tang, J. Yang, Injectable citrate-based
mussel-inspired tissue bioadhesives with high wet strength for sutureless
wound closure, Biomaterials 33 (2012) 7972e7983.
[12] C. Ghobril, M.W. Grinstaff, The chemistry and engineering of polymeric
hydrogel adhesives for wound closure: a tutorial, Chem. Soc. Rev. 44 (2015)
1820e1835.
[13] E.L. Park, J.B. Ulreich, K.M. Scott, N.P. Ullrich, J.A. Linehan, M.H. French, et al.,
Evaluation of polyethylene glycol based hydrogel for tissue sealing after
laparoscopic partial nephrectomy in a porcine model, J. Urol. 172 (2004)
2446e2550.
[14] K.D. Than, C.J. Baird, A. Olivi, Polyethylene glycol hydrogel dural sealant may
reduce incisional cerebrospinal ﬂuid leak after posterior fossa surgery,
Neurosurgery 63 (2008) 182e186.
[15] T.M. Shazly, N. Artzi, F. Boehning, E.R. Edelman, Viscoelastic adhesive me-
chanics of aldehyde-mediated soft tissue sealants, Biomaterials 29 (2008)
4584e4591.
[16] J.K. Tessmar, A.M. Gopferich, Customized PEG-derived copolymers for tissue-
engineering applications, Macromol. Biosci. 7 (2007) 23e39.
[17] W.R. Ranger, D. Halpin, A.S. Sawhney, M. Lyman, J. Locicero, Pneumostasis of
experimental air leaks with a new photopolymerized synthetic tissue sealant,
Am. Surg. 63 (1997) 788e795.
[18] P. Macchiarini, J. Wain, S. Almy, P. Dartevelle, Experimental and clinical
evaluation of a new synthetic, absorbable sealant to reduce air leaks in
thoracic operations, J. Thorac. Cardiovasc. Surg. 117 (1999) 751e758.
[19] E. Buskens, M. Meijboom, H. Kooijman, B. Van Hout, The use of a surgical
sealant (CoSeal®) in cardiac and vascular reconstructive surgery: an economic
analysis, J. Cardiovasc. Surg. 47 (2006) 161.
[20] A. Belboul, L. Dernevik, O. Aljassim, B. Skrbic, G. Radberg, D. Roberts, The effect
of autologous ﬁbrin sealant (Vivostat) on morbidity after pulmonary lobec-
tomy: a prospective randomised, blinded study, Eur. J. Cardiothorac. Surg. 26
(2004) 1187e1191.
[21] A. D'Andrilli, C. Andreetti, M. Ibrahim, A.M. Ciccone, F. Venuta, U. Mansmann,
et al., A prospective randomized study to assess the efﬁcacy of a surgical
sealant to treat air leaks in lung surgery, Eur. J. Cardiothorac. Surg. 35 (2009)
20e21, 817-20; discussion.
[22] L. Bertolaccini, P. Lyberis, E. Manno, Lung sealant and morbidity after pleural
decortication: a prospective randomized, blinded study, J. Cardiothorac. Surg.
5 (2010) 45.
[23] N. Lang, M.J. Pereira, Y. Lee, I. Friehs, N.V. Vasilyev, E.N. Feins, et al., A blood-
resistant surgical glue for minimally invasive repair of vessels and heart de-
fects, Sci. Transl. Med. 6 (2014) 218ra6.
[24] A. Brunelli, M. Monteverde, A. Borri, M. Salati, R.D. Marasco, A. Fianchini,
Predictors of prolonged air leak after pulmonary lobectomy, Ann. Thorac.
Surg. 77 (2004) 1205e1210 discussion 10.
[25] C.M. Elvin, T. Vuocolo, A.G. Brownlee, L. Sando, M.G. Huson, N.E. Liyou, et al.,
A highly elastic tissue sealant based on photopolymerised gelatin, Bio-
materials 31 (2010) 8323e8331.
[26] C. Fuller, Reduction of intraoperative air leaks with Progel in pulmonary
resection: a comprehensive review, J. Cardiothorac. Surg. 8 (2013) 90.
[27] H. Kobayashi, T. Sekine, T. Nakamura, Y. Shimizu, In vivo evaluation of a new
sealant material on a rat lung air leak model, J. Biomed. Mater Res. 58 (2001)
658e665.
[28] J.W. Nichol, S.T. Koshy, H. Bae, C.M. Hwang, S. Yamanlar, A. Khademhosseini,
Cell-laden microengineered gelatin methacrylate hydrogels, Biomaterials 31
(2010) 5536e5544.
[29] K. Yue, G. Trujillo-de Santiago, M.M. Alvarez, A. Tamayol, N. Annabi,
A. Khademhosseini, Synthesis, properties, and biomedical applications of
gelatin methacryloyl (GelMA) hydrogels, Biomaterials 73 (2015) 254e271.
[30] D. Loessner, C. Meinert, E. Kaemmerer, L.C. Martine, K. Yue, P.A. Levett, et al.,
Functionalization, preparation and use of cell-laden gelatin methacryloyl-
based hydrogels as modular tissue culture platforms, Nat. Protoc. 11 (2016)
727e746.
[31] C. Cha, S.R. Shin, X. Gao, N. Annabi, M.R. Dokmeci, X.S. Tang, et al., Controlling
mechanical properties of cell-laden hydrogels by covalent incorporation of
graphene oxide, Small 10 (2014) 514e523.
[32] S.R. Shin, H. Bae, J.M. Cha, J.Y. Mun, Y.C. Chen, H. Tekin, et al., Carbon nanotube
reinforced hybrid microgels as scaffold materials for cell encapsulation, ACS
Nano 6 (2012) 362e372.
[33] J. Visser, D. Gawlitta, K.E. Benders, S.M. Toma, B. Pouran, P.R. van Weeren, et
al., Endochondral bone formation in gelatin methacrylamide hydrogel with
embedded cartilage-derived matrix particles, Biomaterials 37 (2015)
174e182.
[34] J. Hjortnaes, G. Camci-Unal, J.D. Hutcheson, S.M. Jung, F.J. Schoen, J. Kluin, et
al., Directing valvular interstitial cell myoﬁbroblast-like differentiation in a
hybrid hydrogel platform, Adv. Healthc. Mater. 4 (2015) 121e130.
[35] M. Nikkhah, N. Eshak, P. Zorlutuna, N. Annabi, M. Castello, K. Kim, et al.,
Directed endothelial cell morphogenesis in micropatterned gelatin methac-
rylate hydrogels, Biomaterials 33 (2012) 9009e9018.
[36] A.K. Gaharwar, R.K. Avery, A. Assmann, A. Paul, G.H. McKinley,
A. Assmann et al. / Biomaterials 140 (2017) 115e127126
A. Khademhosseini, et al., Shear-thinning nanocomposite hydrogels for the
treatment of hemorrhage, ACS Nano 8 (2014) 9833e9842.
[37] N. Annabi, S.M. Mithieux, P. Zorlutuna, G. Camci-Unal, A.S. Weiss,
A. Khademhosseini, Engineered cell-laden human protein-based elastomer,
Biomaterials 34 (2013) 5496e5505.
[38] L. Zhou, G.X. Tan, Y. Tan, H. Wang, J.W. Liao, C.Y. Ning, Biomimetic minerali-
zation of anionic gelatin hydrogels: effect of degree of methacrylation, Rsc
Adv. 4 (2014) 21997e22008.
[39] T.C. Lai, J. Yu, W.B. Tsai, Gelatin methacrylate/carboxybetaine methacrylate
hydrogels with tunable crosslinking for controlled drug release, J. Mater
Chem. B 4 (2016) 2304e2313.
[40] T. Chen, R. Janjua, M.K. McDermott, S.L. Bernstein, S.M. Steidl, G.F. Payne,
Gelatin-based biomimetic tissue adhesive. Potential for retinal reattachment,
J. Biomed. Mater. Res. Part B, Appl. Biomater. 77 (2006) 416e422.
[41] Y.N. Zhang, R.K. Avery, Q. Vallmajo-Martin, A. Assmann, A. Vegh, A. Memic, et
al., A highly elastic and rapidly crosslinkable elastin-like polypeptide-based
hydrogel for biomedical applications, Adv. Funct. Mater. 25 (2015)
4814e4826.
[42] A. Assmann, K. Zwirnmann, F. Heidelberg, F. Schiffer, K. Horstkotter,
H. Munakata, et al., The degeneration of biological cardiovascular prostheses
under pro-calciﬁc metabolic conditions in a small animal model, Biomaterials
35 (2014) 7416e7428.
[43] U. Anegg, J. Lindenmann, V. Matzi, J. Smolle, A. Maier, F. Smolle-Juttner, Efﬁ-
ciency of ﬂeece-bound sealing (TachoSil) of air leaks in lung surgery: a pro-
spective randomised trial, Eur. J. Cardiothorac. Surg. 31 (2007) 198e202.
[44] B. Qerimi, P. Baumann, J. Husing, H.P. Knaebel, H. Schumacher, Collagen he-
mostat signiﬁcantly reduces time to hemostasis compared with cellulose:
COBBANA, a single-center, randomized trial, Am. J. Surg. 205 (2013) 636e641.
[45] Y. Katagiri, S.A. Brew, K.C. Ingham, All six modules of the gelatin-binding
domain of ﬁbronectin are required for full afﬁnity, J. Biol. Chem. 278 (2003)
11897e11902.
[46] Gorgieva S, Kokol V. Collagen-vs. Gelatine-based Biomaterials and Their
Biocompatibility: Review and Perspectives.
[47] A.K. Lynn, I.V. Yannas, W. Bonﬁeld, Antigenicity and immunogenicity of
collagen, J. Biomed. Mater Res. B Appl. Biomater. 71 (2004) 343e354.
[48] A. Al-Mayah, J. Moseley, M. Velec, K.K. Brock, Sliding characteristic and ma-
terial compressibility of human lung: parametric study and veriﬁcation, Med.
Phys. 36 (2009) 4625e4633.
[49] W. Carver, E.C. Goldsmith, Regulation of tissue ﬁbrosis by the biomechanical
environment, Biomed. Res. Int. 2013 (2013) 101979.
[50] B.L. Hartland, T.J. Newell, N. Damico, Alveolar recruitment maneuvers under
general anesthesia: a systematic review of the literature, Respir. Care 60
(2015) 609e620.
[51] J. Ernsting, Aviation Medicine, 3 ed., Butterworth-Heinemann, Oxford, 1999,
p. 703.
[52] M.S. Allen, D.E. Wood, R.W. Hawkinson, D.H. Harpole, R.J. McKenna,
G.L. Walsh, et al., Prospective randomized study evaluating a biodegradable
polymeric sealant for sealing intraoperative air leaks that occur during pul-
monary resection, Ann. Thorac. Surg. 77 (2004) 1792e1801.
[53] C. Fan, J. Fu, W. Zhu, D.A. Wang, A mussel-inspired double-crosslinked tissue
adhesive intended for internal medical use, Acta biomater. 33 (2016) 51e63.
[54] S. Kull, I. Martinelli, E. Briganti, P. Losi, D. Spiller, S. Tonlorenzi, et al., Glubran2
surgical glue: in vitro evaluation of adhesive and mechanical properties,
J. Surg. Res. 157 (2009) e15e21.
[55] H. Zhang, L.P. Bre, T. Zhao, Y. Zheng, B. Newland, W. Wang, Mussel-inspired
hyperbranched poly(amino ester) polymer as strong wet tissue adhesive,
Biomaterials 35 (2014) 711e719.
[56] A.O. Elzoghby, Gelatin-based nanoparticles as drug and gene delivery sys-
tems: reviewing three decades of research, J. Control Release 172 (2013)
1075e1091.
[57] T. Yu, W. Wang, S. Nassiri, T. Kwan, C. Dang, W. Liu, et al., Temporal and spatial
distribution of macrophage phenotype markers in the foreign body response
to glutaraldehyde-crosslinked gelatin hydrogels, J. Biomater. Sci. Polym. Ed. 27
(2016) 721e742.
[58] M. Giannandrea, W.C. Parks, Diverse functions of matrix metalloproteinases
during ﬁbrosis, Dis. Model Mech. 7 (2014) 193e203.
[59] P.E. Van den Steen, B. Dubois, I. Nelissen, P.M. Rudd, R.A. Dwek,
G. Opdenakker, Biochemistry and molecular biology of gelatinase B or matrix
metalloproteinase-9 (MMP-9), Crit. Rev. Biochem. Mol. Biol. 37 (2002)
375e536.
[60] S.T. Koshy, T.C. Ferrante, S.A. Lewin, D.J. Mooney, Injectable, porous, and cell-
responsive gelatin cryogels, Biomaterials 35 (2014) 2477e2487.
[61] J.Y. Lai, Y.T. Li, Functional assessment of cross-linked porous gelatin hydrogels
for bioengineered cell sheet carriers, Biomacromolecules 11 (2010)
1387e1397.
[62] D.N. Nan, M. Fernandez-Ayala, C. Farinas-Alvarez, R. Mons, F.J. Ortega,
J. Gonzalez-Macias, et al., Nosocomial infection after lung surgery: incidence
and risk factors, Chest 128 (2005) 2647e2652.
[63] J.J. Buckley, P.L. Gai, A.F. Lee, L. Olivi, K. Wilson, Silver carbonate nanoparticles
stabilised over alumina nanoneedles exhibiting potent antibacterial proper-
ties, Chem. Commun. (2008) 4013e4015.
[64] J. Deacon, S.M. Abdelghany, D.J. Quinn, D. Schmid, J. Megaw, R.F. Donnelly, et
al., Antimicrobial efﬁcacy of tobramycin polymeric nanoparticles for Pseu-
domonas aeruginosa infections in cystic ﬁbrosis: formulation, characterisation
and functionalisation with dornase alfa (DNase), J. Control Release 198 (2015)
55e61.
[65] M.S. Hassan, T. Amna, O.B. Yang, M.H. El-Newehy, S.S. Al-Deyab, M.S. Khil,
Smart copper oxide nanocrystals: synthesis, characterization, electrochemical
and potent antibacterial activity, Colloids Surf. B Biointerfaces 97 (2012)
201e206.
A. Assmann et al. / Biomaterials 140 (2017) 115e127 127
